Stocks Health care PMCB

NASDAQ · Health care

PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech, Inc. brought in $0 of revenue over the twelve months to July 31, 2026. It posted a net loss of $16.1M. At July 31, 2026 it held $17.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 14, 2026.

What PharmaCyte Biotech, Inc. does

PharmaCyte Biotech, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PMCB.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What PharmaCyte Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 14, 2026
   Quarterly report 10-Q · period to July 31, 2026Diluted EPS -$0.54 versus -$1.23.
2. July 29, 2026
   Annual report 10-K · period to April 30, 2026Diluted EPS -$2.77 versus $3.19.
3. April 2, 2026
   Executive or director change 8-K
4. March 17, 2026
   Quarterly report 10-Q · period to January 31, 2026Diluted EPS -$0.17 versus -$0.44.
5. March 9, 2026
   Annual report to shareholders ARS
6. March 9, 2026
   Proxy statement DEF 14A
7. February 27, 2026
   Preliminary proxy statement PRE 14A
8. February 13, 2026
   Passive stake changed SCHEDULE 13G/A
9. December 18, 2025
   Quarterly report 10-Q · period to October 31, 2025Diluted EPS -$1.24 versus -$0.39.
10. December 15, 2025
    Late quarterly report notice NT 10-Q

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 17, 2026. Insider transactions on SEC

Insider trades

What the people running PharmaCyte Biotech, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about PMCB

What does PharmaCyte Biotech, Inc. do?

PharmaCyte Biotech, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PMCB.

Is PharmaCyte Biotech, Inc. profitable?

No. Over the twelve months to July 31, 2026 it reported a net loss of $16.1M.

How much revenue does PharmaCyte Biotech, Inc. make?

Over the twelve months to July 31, 2026 PharmaCyte Biotech, Inc. reported revenue of $0.

When did PharmaCyte Biotech, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on September 14, 2026. It covers the period to July 31, 2026.

Similar companies

Compare PMCB with

Compare PMCB with any company

Follow PMCB

Get an email when PharmaCyte Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PMCB: get an email when it files

Where the numbers come from

Financial figures are the values PharmaCyte Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.